TW202142230A - 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法 - Google Patents

用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法 Download PDF

Info

Publication number
TW202142230A
TW202142230A TW110102913A TW110102913A TW202142230A TW 202142230 A TW202142230 A TW 202142230A TW 110102913 A TW110102913 A TW 110102913A TW 110102913 A TW110102913 A TW 110102913A TW 202142230 A TW202142230 A TW 202142230A
Authority
TW
Taiwan
Prior art keywords
subject
dose
weeks
cancer
antibody
Prior art date
Application number
TW110102913A
Other languages
English (en)
Chinese (zh)
Inventor
凱瑟琳 賴
劉玉儀
安東尼 鐘哈 李
石 李
伊凡 蓋爾 林劉
克莉絲汀娜 吉恩 馬瑟尼
黛安娜 門杜斯
雷蒙 Ｄ 蒙
德 安 阮
吉爾帕 布潘達 派托爾
清廣 范
伊莎貝爾 安 魯尼
海瑟 布萊斯 史蒂文斯
莎拉 瑪麗 脫特曼
麗佳 王
宇雷 王
派翠克 喬治 羅伯特 威廉斯
本傑明 吳
顏宜彬
張愛晶
張曉松
馬克斯 戴爾 貝林格
希拉 巴瑞克
伊莉莎白 亞歷山卓 班尼特
馬賽拉 盧西亞 卡斯楚
艾德華 南塞克 查
陳慧敏
崔仁智
克里斯多夫 羅蘭 寇特
威拉 維內 德岡卡爾
芭芭拉 珍妮佛 吉里茲
黃田
金柏莉 馬尤米 科馬蘇巴拉
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/024526 external-priority patent/WO2021194481A1/en
Priority claimed from PCT/US2020/049415 external-priority patent/WO2022050954A1/en
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW202142230A publication Critical patent/TW202142230A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
TW110102913A 2020-01-27 2021-01-26 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法 TW202142230A (zh)

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
US202062966448P 2020-01-27 2020-01-27
US62/966,448 2020-01-27
US202062985822P 2020-03-05 2020-03-05
US62/985,822 2020-03-05
US202062994272P 2020-03-24 2020-03-24
PCT/US2020/024526 WO2021194481A1 (en) 2020-03-24 2020-03-24 Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WOPCT/US20/24526 2020-03-24
US62/994,272 2020-03-24
US202063059054P 2020-07-30 2020-07-30
US63/059,054 2020-07-30
US202063059960P 2020-07-31 2020-07-31
US63/059,960 2020-07-31
US202063074807P 2020-09-04 2020-09-04
US202063074827P 2020-09-04 2020-09-04
US63/074,827 2020-09-04
WOPCT/US20/49415 2020-09-04
PCT/US2020/049415 WO2022050954A1 (en) 2020-09-04 2020-09-04 Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US63/074,807 2020-09-04
US202063085890P 2020-09-30 2020-09-30
US63/085,890 2020-09-30
US202063105198P 2020-10-23 2020-10-23
US63/105,198 2020-10-23
US202063114517P 2020-11-16 2020-11-16
US63/114,517 2020-11-16
US202063124693P 2020-12-11 2020-12-11
US63/124,693 2020-12-11
US202063127109P 2020-12-17 2020-12-17
US63/127,109 2020-12-17

Publications (1)

Publication Number Publication Date
TW202142230A true TW202142230A (zh) 2021-11-16

Family

ID=74626264

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110102913A TW202142230A (zh) 2020-01-27 2021-01-26 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法

Country Status (10)

Country Link
EP (1) EP4096646A1 (ja)
JP (1) JP2023511595A (ja)
KR (1) KR20220133243A (ja)
CN (1) CN115315256A (ja)
AU (1) AU2021212662A1 (ja)
CA (1) CA3165187A1 (ja)
IL (1) IL294800A (ja)
MX (1) MX2022009170A (ja)
TW (1) TW202142230A (ja)
WO (1) WO2021154761A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022015877A (es) * 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
CA3223534A1 (en) * 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
JP2024527049A (ja) * 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド がんを治療するための方法及び組成物
WO2023018675A1 (en) * 2021-08-10 2023-02-16 Merck Sharp & Dohme Llc A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
JP2024532744A (ja) * 2021-08-10 2024-09-10 メルク・シャープ・アンド・ドーム・エルエルシー Ｔ１ｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及び（１又は複数の）化学療法剤を含む治療的組合せ
WO2023040804A1 (zh) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法
KR20240055080A (ko) * 2021-09-15 2024-04-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
KR20240121771A (ko) * 2021-12-22 2024-08-09 제넨테크, 인크. 항-tigit 항체의 임상 제제
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
WO2024130026A1 (en) * 2022-12-16 2024-06-20 Elevar Therapeutics, Inc. Methods and compositions for treatment of subjects with hepatic impairments
WO2024135809A1 (ja) * 2022-12-23 2024-06-27 東レ株式会社 癌の治療及び／又は予防のための医薬品

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE122005000053I2 (de) 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PT836605E (pt) 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
EP0980244B1 (en) 1997-05-06 2003-06-04 Wyeth Holdings Corporation Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
KR20010031813A (ko) 1997-11-06 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
HUP0104211A3 (en) 1998-11-19 2003-01-28 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
EP2898329B1 (en) 2012-09-24 2017-05-17 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
CN107667119A (zh) 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
EP4335931A3 (en) 2015-05-29 2024-06-19 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
CN111836831A (zh) * 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药

Also Published As

Publication number Publication date
CN115315256A (zh) 2022-11-08
MX2022009170A (es) 2022-08-17
IL294800A (en) 2022-09-01
WO2021154761A1 (en) 2021-08-05
JP2023511595A (ja) 2023-03-20
KR20220133243A (ko) 2022-10-04
AU2021212662A1 (en) 2022-08-11
CA3165187A1 (en) 2021-08-05
EP4096646A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
TW202142230A (zh) 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法
US20180346586A1 (en) Methods of treating cancer using anti-ox40 antibodies
US20180256711A1 (en) Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA3038712A1 (en) Therapeutic and diagnostic methods for cancer
US20220016243A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
TWI836278B (zh) 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
US20240252632A1 (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
CN115916348A (zh) 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
TW202015730A (zh) 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
TW202126690A (zh) 用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
WO2021222167A1 (en) Methods and compositions for non-small cell lung cancer immunotherapy
TW202320848A (zh) 治療癌症之方法及組成物
TW202426505A (zh) 癌症之治療及診斷方法